Introduction:

In a strongly worded judgment underscoring the critical link between procedural discipline and public health protection, the Bombay High Court at Nagpur expressed serious concern over repeated and systemic lapses by officers of the Drugs Department in complying with the mandatory timelines prescribed under Rule 45 of the Drugs and Cosmetics Rules, 1945, and held that such delays not only vitiate criminal prosecutions but also allow sub-standard medicines to remain in circulation, thereby endangering human life. The matter arose before Justice M. M. Nerlikar in a criminal writ petition filed by the Directors of M/s Oscar Remedies Pvt. Ltd., including Mr. Ashwani Lamba and others, who sought quashing of a criminal prosecution pending before the Chief Judicial Magistrate, Gadchiroli, for allegedly manufacturing a drug that was declared “not of standard quality.” As per the prosecution, a Drug Inspector had drawn samples of the drug on 12 July 2022 and forwarded them to the Government Analyst on 14 July 2022, but the Analyst sought extension for analysis only on 1 November 2022, long after the mandatory sixty-day period prescribed under Rule 45 had expired. The final report declaring the drug sub-standard was issued only on 18 January 2023, and despite this extraordinary delay, prosecution was launched in August 2023, while the manufacturer was informed nearly four months after the report was received. The petitioners challenged the prosecution on the ground that the mandatory procedure under Rule 45 had been violated, depriving them of their statutory right to seek re-analysis of the sample, thereby rendering the entire prosecution legally unsustainable. While the immediate question before the Court concerned the legality of the prosecution, the Court expanded its scrutiny to examine the broader pattern of administrative apathy within the Drugs Department and its direct impact on the enforcement of drug safety laws, leading to far-reaching directions aimed at reforming the testing and reporting system across the State of Maharashtra.

Arguments:

The petitioners contended that the entire prosecution was vitiated due to non-compliance with the mandatory timelines under Rule 45 of the Drugs and Cosmetics Rules, 1945, which obligates the Government Analyst to furnish a test report within sixty days of receipt of the sample and permits extension only if sought within that period by recording specific reasons. It was argued that in the present case, not only was the report furnished far beyond the statutory period, but even the request for extension was made after the expiry of the sixty-day window, rendering it legally meaningless. Relying on the earlier decision in Swapnil s/o Liladhar Mane vs. State of Maharashtra, the petitioners submitted that delayed analysis deprives manufacturers of their valuable statutory right to apply for re-analysis by the Central Drugs Laboratory, a safeguard designed to ensure fairness and accuracy in prosecutions under the Act. They further contended that the delay in issuing notice to the manufacturer, even after receipt of the adverse report, compounded the illegality and demonstrated gross administrative negligence. According to the petitioners, criminal liability under the Drugs and Cosmetics Act cannot be sustained when the foundational procedural safeguards meant to balance regulatory enforcement with principles of natural justice are violated. On the other hand, the State sought to justify the prosecution by arguing that the drug had in fact been found to be sub-standard and that technical lapses in timelines should not shield manufacturers from accountability, especially when public health is involved. It was submitted that delays often occur due to heavy workload, shortage of laboratories, and administrative constraints, and that the core objective of the statute is to ensure that unsafe drugs are removed from the market and offenders are prosecuted. The State argued that quashing prosecutions on procedural grounds may embolden unscrupulous manufacturers and undermine regulatory enforcement. However, the petitioners countered that statutory timelines are not empty formalities but essential components of fair process, and that enforcement agencies cannot benefit from their own lapses while exposing citizens to prolonged legal jeopardy. The central legal conflict therefore revolved around whether procedural non-compliance could be overlooked in the name of public interest, or whether strict adherence to statutory safeguards is itself an integral part of protecting public health and maintaining the credibility of regulatory enforcement.

Court’s Judgment:

After examining the statutory framework and the factual chronology, the Bombay High Court held that the failure of the Government Analyst to furnish the test report within sixty days, coupled with the belated and invalid request for extension, constituted a clear violation of Rule 45, and that such violation struck at the root of the prosecution. The Court reiterated that Rule 45 is mandatory in nature and not merely directory, as it protects the statutory right of the accused to seek re-analysis of the sample, which is a crucial safeguard against erroneous or arbitrary prosecution. The Court observed that once the statutory period lapses without valid extension, continuation of prosecution becomes legally impermissible. Justice Nerlikar further expressed surprise and concern at the “leniency” shown by the authorities, noting that even after receiving the adverse report on 18 January 2023, the notice to the manufacturer was served only on 19 April 2023, reflecting a casual and indifferent approach to enforcement of drug safety laws. While quashing the prosecution, the Court made strong institutional observations, stating that there are numerous cases where departmental lapses benefit manufacturers of sub-standard drugs and defeat the very object of the Drugs and Cosmetics Act, 1940, which is aimed at safeguarding human health. The Court stressed that allowing such drugs to remain in circulation due to bureaucratic inefficiency directly harms citizens on a large scale, and that officers entrusted with public health responsibilities cannot afford to be indifferent to statutory mandates. Recognizing that systemic issues such as workload and infrastructure shortages may contribute to delays, the Court nevertheless held that administrative constraints cannot justify violation of mandatory legal duties. Accordingly, while granting relief to the petitioners by quashing the criminal proceedings, the Court issued comprehensive directions to the Commissioner of Food and Drugs Administration, Maharashtra, to ensure strict compliance with Rule 45 timelines, to take disciplinary action against officers who fail to adhere to statutory obligations, to request the Government to establish additional laboratories if workload is causing delays, to require Government Analysts to seek extensions immediately with written reasons when the sixty-day limit cannot be met, to develop an efficient online system for real-time tracking of drug samples and test reports, and to web-host the entire testing process so that all stakeholders are aware of the status and outcome of analysis. The Court listed the matter for compliance reporting on 4 May 2026, thereby converting an individual grievance into an opportunity for structural reform of the drug regulatory mechanism, and sending a clear message that procedural discipline is inseparable from effective public health protection.